Targeted Cancer Therapy Market Forecasts to 2030 – Global Analysis By Type (Monoclonal Antibodies, Rituximab, Small-Molecules, Amino Acids, Immunotoxins, Diphtheria toxin (DT), Pseudomonas exotoxins and Other Types), By Cancer Type (Lung Cancer, Breast Ca

Targeted Cancer Therapy Market Forecasts to 2030 – Global Analysis By Type (Monoclonal Antibodies, Rituximab, Small-Molecules, Amino Acids, Immunotoxins, Diphtheria toxin (DT), Pseudomonas exotoxins and Other Types), By Cancer Type (Lung Cancer, Breast Cancer, Colorectal Cancer, Blood Cancer, Gynecologic Cancer and Other Cancer Types), By Route of Administration (Oral, Parenteral and Other Route of Administrations), Distribution Channel, End User and By Geography

According to Stratistics MRC, the Global Targeted Cancer Therapy Market is accounted for $76.1 billion in 2023 and is expected to reach $137.4 billion by 2030 growing at a CAGR of 8.8% during the forecast period. Targeted cancer therapy is a precision medicine approach that involves using drugs or other substances to specifically identify and attack cancer cells while minimizing damage to healthy cells. This method aims to disrupt the growth and survival of cancer cells, often resulting in fewer side effects compared to traditional chemotherapy.

According to the American Cancer Society reports nearly 1.7 million new cancer cases are expected to be diagnosed in 2019 in the U.S. Similarly, according to the National Cancer Institute, in 2018, around 1,735,350 new cases of cancer were diagnosed in U.S. and 609,640 people died from the disease.

Market Dynamics:

Driver:

Increasing global cancer prevalence

There is a growing need for more effective and targeted treatment approaches. Targeted Cancer Therapy offers precision in addressing specific molecular and genetic aberrations driving cancer, leading to enhanced therapeutic outcomes. The rising burden of diverse cancer types, coupled with advancements in understanding the genetic basis of cancers, propels the development and adoption of targeted therapies. This driver underscores the urgency to develop innovative and personalized treatment options, aligning with the global healthcare imperative to improve cancer care and outcomes in the face of a rising and diverse cancer landscape.

Restraint:

Financial burden associated with targeted therapies

These therapies offer precise and effective treatments, their high costs often create challenges in terms of affordability and accessibility. The development and production of targeted cancer drugs involve complex processes and substantial research investments, leading to elevated pricing. Additionally, the need for ongoing monitoring, molecular testing, and personalized treatment plans contribute to the overall financial strain on patients and healthcare systems. The expense associated with targeted therapies may limit access for certain patient populations, raising concerns about healthcare disparities.

Opportunity:

Supportive policies and funding for cancer research

Governments and healthcare organizations worldwide are increasingly recognizing the potential of targeted therapies in revolutionizing cancer treatment. Initiatives that foster research, development, and clinical trials through funding and supportive policies create an environment conducive to innovation. This financial backing accelerates the discovery of novel targeted therapies, expedites regulatory approvals, and enhances market accessibility. The collaboration between public and private sectors, backed by robust funding, not only propels scientific advancements but also ensures that cutting-edge targeted cancer therapies can reach patients more swiftly, addressing unmet medical needs and contributing to the evolution of cancer care.

Threat:

Adverse effects associated with targeted therapies

While these therapies aim for precision in attacking cancer cells, off-target effects and unintended consequences may lead to adverse reactions. Patients undergoing targeted therapy may experience side effects such as fatigue, skin reactions, gastrointestinal issues, and immune-related complications. Additionally, the potential for resistance to targeted drugs and long-term effects remains a concern. Adverse effects not only impact the quality of life for patients but may also result in treatment discontinuation.

Covid-19 Impact:

The Covid-19 pandemic has significantly impacted the market. Disruptions in healthcare systems, reprioritization of resources, and delays in clinical trials have hindered the development and accessibility of targeted therapies. Patient concerns and logistical challenges have affected treatment adherence. However, the pandemic has underscored the importance of innovative therapies, accelerating the adoption of telemedicine and digital health solutions in cancer care.

The breast cancer segment is expected to be the largest during the forecast period

The breast cancer segment is expected to have a lucrative growth. Targeted therapies for breast cancer include drugs like HER2 inhibitors and CDK4/6 inhibitors, aiming to address specific molecular characteristics. These therapies offer improved efficacy with fewer side effects compared to conventional treatments. The evolving landscape of targeted therapies for breast cancer underscores the commitment to personalized medicine, providing more tailored and effective treatment options for patients, particularly those with HER2-positive or hormone receptor-positive breast cancer subtypes.

The hospitals segment is expected to have the highest CAGR during the forecast period

The hospitals segment is anticipated to witness the fastest CAGR growth during the forecast period. They provide a crucial infrastructure for patient diagnosis, treatment planning, and the delivery of targeted therapies. With specialized oncology departments and multidisciplinary teams, hospitals facilitate patient access to cutting-edge targeted cancer therapies. Additionally, hospitals contribute to clinical trials, research collaborations, and the overall advancement of personalized cancer care, making them central to the evolving landscape of targeted therapy interventions.

Region with largest share:

During the forecast period, it is expected that the North American Targeted Cancer Therapy market will continue to hold a majority of the market share. The region's robust pharmaceutical industry and supportive regulatory environment foster the development and adoption of innovative targeted therapies. Additionally, collaborations between academia, research institutions, and biopharmaceutical companies contribute to the rapid evolution of precision medicine approaches. North America continues to be a key hub for clinical trials, driving advancements in personalized cancer treatment and influencing global trends in the Targeted Cancer Therapy landscape.

Region with highest CAGR:

Asia Pacific is projected to have the highest CAGR over the forecast period. Factors such as increasing cancer incidence, rising healthcare awareness, and advancements in personalized medicine contribute to market expansion. Countries like China, Japan, and India are witnessing significant research and development activities, fostering the adoption of targeted therapies. The region's evolving healthcare infrastructure and supportive regulatory environments position Asia Pacific as a key hub for the development, commercialization, and adoption of innovative targeted cancer treatments.

Key players in the market

Some of the key players in Targeted Cancer Therapy market include Abbott, Pfizer Inc., Sun Pharmaceutical Industries Ltd., Amneal Pharmaceuticals LLC., Novartis AG, Aurobindo Pharma, Mirati Therapeutics, Inc, Bayer AG, Merck & Co. Inc., Bristol-Myers Squibb Company, Cipla Inc., F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Johnson & Johnson, Hikma Pharmaceuticals PLC and ImmunoGen, Inc.

Key Developments:

In July 2023, Genentech, Inc received approval from United States FDA for Tecentriq (atezolizumab) for adult and pediatric patients two years of age and older with unresectable or metastatic alveolar soft part sarcoma (ASPS).

In December 2022, AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) was approved in the United States for the treatment of adult patients with unresectable or metastatic non-small cell lung cancer (NSCLC) whose tumors have activating HER2 (ERBB2) mutations, as detected by an FDA-approved test, and who have received prior systemic therapy.

Types Covered:
• Monoclonal Antibodies
• Rituximab
• Small-Molecules
• Amino Acids
• Immunotoxins
• Diphtheria toxin (DT)
• Pseudomonas exotoxins
• Other Types

Cancer Types Covered:
• Lung Cancer
• Breast Cancer
• Colorectal Cancer
• Blood Cancer
• Gynecologic Cancer
• Other Cancer Types

Route of Administrations Covered:
• Oral
• Parenteral
• Other Route of Administrations

Distribution Channels Covered:
• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

End Users Covered:
• Hospitals
• Cancer and Radiation Therapy Centers
• Specialty Clinics
• Other End Users

Regions Covered:
• North America
US
Canada
Mexico
• Europe
Germany
UK
Italy
France
Spain
Rest of Europe
• Asia Pacific
Japan
China
India
Australia
New Zealand
South Korea
Rest of Asia Pacific
• South America
Argentina
Brazil
Chile
Rest of South America
• Middle East & Africa
Saudi Arabia
UAE
Qatar
South Africa
Rest of Middle East & Africa

What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements